PMV Pharmaceuticals, Inc. (PMVP)
1.27
-0.04
(-2.68%)
USD |
NASDAQ |
Oct 23, 16:00
1.275
0.00 (0.00%)
After-Hours: 20:00
PMV Pharmaceuticals Enterprise Value : -11.32M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -11.32M |
| October 22, 2026 | -9.448M |
| October 21, 2026 | -6.508M |
| October 20, 2026 | -4.904M |
| October 19, 2026 | -12.12M |
| October 16, 2026 | -14.53M |
| October 15, 2026 | -10.25M |
| October 14, 2026 | -12.92M |
| October 13, 2026 | -7.042M |
| October 12, 2026 | -3.835M |
| October 09, 2026 | 2.046M |
| October 08, 2026 | 0.442M |
| October 07, 2026 | 0.9766M |
| October 06, 2026 | 6.857M |
| October 05, 2026 | 15.95M |
| October 02, 2026 | 16.48M |
| October 01, 2026 | 14.34M |
| September 30, 2026 | 10.06M |
| September 29, 2026 | -2.766M |
| September 28, 2026 | -6.508M |
| September 25, 2026 | -8.112M |
| September 24, 2026 | -7.844M |
| September 23, 2026 | -5.973M |
| September 22, 2026 | 1.511M |
| September 21, 2026 | -0.3599M |
| Date | Value |
|---|---|
| September 18, 2026 | 0.9766M |
| September 17, 2026 | -1.162M |
| September 16, 2026 | -2.766M |
| September 15, 2026 | -6.508M |
| September 14, 2026 | -1.162M |
| September 11, 2026 | -4.369M |
| September 10, 2026 | -2.231M |
| September 09, 2026 | -5.706M |
| September 08, 2026 | -7.577M |
| September 04, 2026 | -10.25M |
| September 03, 2026 | -12.92M |
| September 02, 2026 | -11.85M |
| September 01, 2026 | -10.25M |
| August 31, 2026 | -14.53M |
| August 28, 2026 | -13.99M |
| August 27, 2026 | -12.92M |
| August 26, 2026 | -9.181M |
| August 25, 2026 | -9.448M |
| August 24, 2026 | -9.448M |
| August 21, 2026 | -8.112M |
| August 20, 2026 | -9.716M |
| August 19, 2026 | -10.78M |
| August 18, 2026 | -12.92M |
| August 17, 2026 | -12.39M |
| August 14, 2026 | -11.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.09M |
| Total Expenses (Quarterly) | 18.09M |
| EPS Diluted (Quarterly) | -0.3388 |
| Earnings Yield | -111.3% |
| Normalized Earnings Yield | -111.25 |